Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.18, $0.27 worse than the analyst estimate of $1.45. Revenue for the quarter came in at $11.44 billion versus the consensus estimate of $12.09 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2024 EPS of $13.02-$13.52, versus the consensus of $13.50. Eli Lilly & Co. sees FY2024 revenue of $45.4-46 billion, versus the consensus of $46.25 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.